Objective: Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity, most clinicians are not familiar with their diagnosis and management. This practice guideline summarizes the diagnosis and management of lipodystrophy syndromes not associated with HIV or injectable drugs.
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Metabolic complications are frequent and may be severe. Cardiomyopathy or rhythm disturbances may occur.
Familial partial lipodystrophy
FPLD is a group of usually autosomal dominant disorders characterized by loss of fat affecting the limbs, buttocks, and hips (10) . Regional excess fat accumulation is frequent, varies by subtype, and may result in a Cushingoid appearance. Fat distribution is typically normal in early childhood, with loss of fat occurring around puberty. Muscular hypertrophy is common. Metabolic complications are common in adulthood (14) , with increased risk of coronary heart disease (15) and occasionally early cardiomyopathy.
Acquired generalized lipodystrophy (Lawrence syndrome)
AGL is more common in females (females:males, 3:1) and appears usually before adolescence (but may develop at any time in life) with progressive loss of fat affecting the whole body including palms and soles (4) . Some fat accumulation can appear in the face, neck, or axillae. Meta- bolic complications are frequent and may be severe. AGL is often associated with autoimmune diseases (4, 16) .
Acquired partial lipodystrophy (Barraquer-Simons syndrome)
APL is more frequent in females (females:males, 4:1) and usually begins in childhood or adolescence. Loss of fat follows a cranio-caudal trend, progressively affecting the face, neck, shoulders, arms, and trunk. Fat accumulation can appear in the hips, buttocks, and legs (17) . APL is associated with autoimmune diseases, especially membranoproliferative glomerulonephritis (MPGN) in approximately 20% (17) . Most patients have low serum complement 3 (C3) levels, and some have presence of C3 nephritic factor. Metabolic complications are uncommon (17) .
Diagnosis of Lipodystrophy
• Diagnosis of lipodystrophy is based on history, physical examination, body composition, and metabolic status. Firm diagnostic criteria for lipodystrophy have not been established. Figure 2 shows a suggested diagnostic approach.
Establishing the presence of lipodystrophy
Lipodystrophy should be suspected in patients with regional or generalized lack of adipose tissue outside of the normal range by physical examination, which can be supported by anthropometry, dual energy x-ray absorptiometry, and whole-body magnetic resonance imaging (Supplemental Table 3 ) (18) . Recognizing the loss of sc fat is particularly challenging in partial lipodystrophy and especially in men, in whom low body fat overlaps with normal variation and metabolic manifestations of lipodystrophy are less severe. In both genetic and acquired lipodystrophies, the loss of fat may be gradual, delaying diagnosis.
Physical, historical, and comorbid features that increase the suspicion of lipodystrophy (18) are shown in Table 3 .
Because serum leptin assays are not standardized and leptin concentrations in patients with lipodystrophy (especially partial forms) overlap the general population, leptin levels do not help in diagnosis but may help with the choice of therapies.
Differential diagnosis
Differential diagnosis should include conditions presenting with severe weight loss (malnutrition, anorexia nervosa, uncontrolled diabetes mellitus, thyrotoxicosis, adrenocortical insufficiency, cancer cachexia, HIV-associated wasting, chronic infections). Especially difficult is differentiating lipodystrophy from uncontrolled diabetes because both may have extreme hypertriglyceridemia. However, restoring glycemic control in patients with nonlipodystrophic diabetes leads to a regain of body fat. Generalized lipodystrophies can be confused with mutations of the insulin receptor or acromegaly/gigantism, and FPLD with Cushing's syndrome, truncal obesity, and multiple symmetric lipomatosis.
Establishing the subtype of lipodystrophy

Pattern of fat loss
Although the pattern of body fat loss in patients with a particular subtype of genetic lipodystrophy is quite characteristic, heterogeneity occurs in the onset, severity, and pattern of fat loss, even within families.
Distinguishing genetic from acquired lipodystrophy
Pedigree analysis can suggest genetic vs acquired lipodystrophy. Review of photographs from infancy may distinguish CGL from AGL because infants typically show absent fat in CGL and normal fat in AGL. However, there have been cases of AGL with loss of fat during the first few months of life (4). Patients with AGL lack family history but can be confused with any type of genetic lipodystrophy, especially de novo mutations.
The presence of autoimmune diseases (myositis, type 1 diabetes, autoimmune hepatitis, and others) (4, 10, 16, 17, 19, 20) increases the suspicion of acquired lipodystrophy. In APL, low serum C3, C3 nephritic factor, proteinuria, or biopsy-proven MPGN support the diagnosis.
Genetic testing
Genotyping may include limited candidate gene sequencing, a panel of candidate genes, or whole-exome/ whole-genome sequencing. The website www.genetests. org lists clinical and research laboratories conducting genetic testing for lipodystrophy syndromes. Because there is strong evidence for additional loci for genetic lipodystrophies, negative tests do not rule out a genetic condition. press.endocrine.org/journal/jcem
Genetic counseling and screening of family members
Genetic counseling must take into consideration that the current understanding of the natural history of genetic lipodystrophies is incomplete. In affected pedigrees, premarital counseling with genetic testing to detect carrier status can be considered.
Clinical diagnosis of lipodystrophy may be difficult in men (21) , and some genotypes are associated with mild lipodystrophy phenotypes (22, 23) . Genetic screening of family members may help identify individuals with subtle phenotypes. Genetic screening may be particularly important for families with specific LMNA mutations associated with cardiomyopathy and arrhythmia.
Screening for Comorbidities
All patients should be screened for diabetes, dyslipidemia, NAFLD, and cardiovascular and reproductive dysfunction. Because patients with APL are at low risk for metabolic complications, clinical judgment should guide follow-up screening. Screening for comorbidities specific to individual lipodystrophy subtypes is not extensively discussed here.
Diabetes mellitus
• In addition to physical examination, ultrasound and elastography are useful to estimate liver and spleen size, severity of steatosis and fibrosis, and existence of portal hypertension. Patients with CGL2 are at high risk for early cirrhosis, and those with AGL may have autoimmune hepatitis in addition to NAFLD (19) . . Diagnostic approach to lipodystrophy syndromes. Lipodystrophy should be suspected in patients with regional or generalized lack of adipose tissue. History should assess age of onset of fat loss and comorbidities. Physical examination should determine distribution of sc fat loss and presence of prominent muscles, phlebomegaly, acanthosis nigricans, hepatomegaly, xanthomas, and acromegaloid or progeroid appearance. All patients should undergo a metabolic workup for insulin resistance, diabetes, dyslipidemia, and fatty liver disease. Conventional anthropometry including skinfold thickness measurements, Ϯ dual energy x-ray absorptiometry, and whole-body magnetic resonance imaging (if available) should be performed to confirm the pattern of fat loss. Common genetic lipodystrophies include CGL, FPLD, and progeroid lipodystrophies. They require genotyping to confirm the diagnosis, followed by genetic counseling and screening of family members. Patients with progeroid lipodystrophies have progeroid features like bird-like facies, high-pitched voice, skin atrophy and pigmentation, alopecia, and nail dysplasia. Hypertension is common (25) , even in children. In patients with CGL4, atypical progeroid syndromes, and FPLD2 due to LMNA mutations, cardiac abnormalities including ischemic heart disease, cardiomyopathy, arrhythmias, and sudden death are reported (3, 23, 26 -33) .
Kidney disease
• Urine protein should be measured annually using 24- hour urine collection or spot urine protein-to-creatinine ratio. (Class IIa, Level C)
Proteinuria is common (34) . Kidney biopsy should be performed as clinically indicated, and pathology may include diabetic nephropathy, focal segmental glomerulosclerosis (especially in CGL) (34) or MPGN (especially in APL) (17) .
Malignancy
Lymphomas, particularly peripheral T-cell lymphoma, occur in AGL, with a prevalence of approximately 7% (4, 35) . Appropriate screening has not been established but would reasonably include annual skin and lymph node examination. Generalized lipodystrophy has been reported as a paraneoplastic manifestation of pilocytic astrocytoma in three children who regained body fat after cancer therapy (36) . Clinicians should consider screening for brain tumors in children who present with idiopathic AGL or atypical CGL. Specific progeroid syndromes (eg, Bloom and Werner syndromes) are associated with increased malignancy risk (Supplemental Table 2 ).
Treatment of Lipodystrophy Syndromes
Current therapies prevent or ameliorate the comorbidities of lipodystrophy syndromes. There is no cure for lipodystrophy and no treatment that can regrow adipose tissue. The cornerstone of therapy for metabolic complications of lipodystrophy is diet. Studies of specific diets in (37) , but dietary restriction is challenging to achieve. Food restriction to control metabolic complications must be balanced by requirements for growth in children. Overfeeding to achieve normal weight may worsen metabolic complications and hepatic steatosis. Assessment of weight-for-length and body mass index by comparison to reference growth data is not appropriate because body composition is atypical. Low weight-forlength or body mass index is acceptable provided linear growth is maintained.
Patients should follow a 50 -60% carbohydrate, 20 -30% fat, and approximately 20% protein diet. Simple sugars should be restricted in preference for high-fiber complex carbohydrates, distributed evenly among meals and snacks and consumed in combination with protein or fat. Dietary fat should be primarily cis-mono-unsaturated fats and long-chain omega-3 fatty acids. In extremely hypertriglyceridemic infants, medium-chain triglyceridebased formula may help (38, 39) . During acute pancreatitis, bowel rest followed by a very-low-fat (Ͻ20 g) diet should be used. Currently, metreleptin (recombinant human methionyl leptin) is the only drug approved specifically for lipodystrophy. It is approved in the United States as an adjunct to diet for treatment of metabolic complications in patients with generalized lipodystrophy (http://www.fda.gov/News Events/Newsroom/PressAnnouncements/ucm387060. htm). In Japan, it is approved for both generalized and partial lipodystrophy (http://www.shionogi.co.jp/en/company/ news/2013/pmrltj0000000ufd-att/e_130325.pdf). It is available in other parts of the world (eg, Europe) through compassionate use programs. There is no age limit for initiation of metreleptin; children as young as 6 months have been treated. A dosing algorithm is provided in Supplemental Table 4 (40) . Dose adjustments should be made in response to metabolic parameters and weight change, with clinical and laboratory assessment performed every 3-6 months.
Metreleptin in generalized lipodystrophy
Metreleptin decreases hyperphagia (41) (42) (43) (44) (45) , frequently leading to weight loss. Reduced food intake is at least partially responsible for many of the metabolic improvements. If excessive weight loss occurs, the dose of metreleptin should be reduced (Supplemental Table 4 ) (40) .
Metreleptin markedly improved fasting glucose as early as the first week (42) and lowered HbA1c by 2% after 1 year (46) . To reduce the risk of hypoglycemia, frequent glucose monitoring is recommended. Providers should consider reducing insulin doses by approximately 50% on initiation of metreleptin in patients with wellcontrolled diabetes. Many young patients with CGL are able to discontinue insulin (46) .
Metreleptin lowered triglycerides within 1 week (42), reaching 60% reduction at 1 year (46) . Metreleptin also decreased LDL-and total cholesterol but did not change HDL-cholesterol (47, 48) . Acute pancreatitis due to hypertriglyceridemia has occurred in patients who acutely discontinued or reduced metreleptin (47) .
Metreleptin reduced hepatic steatosis, serum transaminases, and NASH scores within 6 to 12 months (42, 49 -51) . In one case, metreleptin ameliorated recurrence of severe hepatic steatosis after liver transplantation (52) .
Metreleptin decreased proteinuria in most patients (34, 42) . However, four patients had worsened renal disease during metreleptin treatment, so renal function should be monitored closely with preexisting renal disease (34) .
In females, metreleptin normalized gonadotropin secretion, leading to normal progression of puberty, normalization of menstrual periods (42, 45, 53, 54) , and improved fertility (1). Metreleptin decreased T in women but did not alter ovarian morphology (45, 53, 55) . In males, metreleptin increased T (45).
Metreleptin in partial lipodystrophy
The response to metreleptin in partial lipodystrophy is less robust than in generalized lipodystrophy. In one study, metreleptin reduced hypertriglyceridemia and improved glycemia in severely hypoleptinemic patients with partial lipodystrophy and severe metabolic derangements (baseline HbA1c Ͼ8%, triglycerides Ͼ500 mg/dL, leptin Ͻ4 ng/mL) (46) . In a second study, metreleptin improved triglycerides and indices of insulin sensitivity and secretion in FPLD2 patients with moderate to severe hypoleptinemia (56) . However, in a third study, no glycemic improvement was observed in FPLD2 patients with serum leptin Ͻ7 ng/mL (57) . Metreleptin is only available to patients with partial lipodystrophy through clinical trials, compassionate use programs, and in Japan.
Side effects of metreleptin
Approximately 30% of patients experience side effects (47) . The most clinically important are hypoglycemia (in patients receiving concomitant insulin) and infrequent injection-site reactions (erythema, urticaria).
In vivo neutralizing antibody activity to leptin has been reported (58, 59) . The clinical implications remain unclear, but may include treatment failure and sepsis (59) . Additional serious adverse events occurring during metreleptin treatment are likely related to the underlying lipodystrophy syndrome, rather than metreleptin. These include T-cell lymphoma in patients with AGL (35), pancreatitis (47) , and worsening of liver (47) and kidney (34) disease. Among the oral hypoglycemic agents, metformin is used most frequently. In patients with partial lipodystrophy, thiazolidinediones improved HbA1c, triglycerides, hepatic volume, and steatosis but may increase regional fat excess (Supplemental Table 5 ) (60, 61) . In patients with high insulin requirements, concentrated insulins should be considered (62) . Insulin glargine and degludec kinetics may be altered when injected in lipodystrophic areas because their long duration of action requires sc fat (63, 64) . Patients with generalized lipodystrophy may have to take insulin by im routes for the lack of sc fat. Many other hypoglycemic agents have been used in lipodystrophy, but their efficacy has not been studied.
Additional treatments for specific comorbidities
Diabetes
Dyslipidemia
• Statins should be used concomitantly with lifestyle modification (after consideration of age, reproductive status, and tolerance). (Class 1, Level C) • Fibrates and/or long-chain omega-3 fatty acids should be used for triglycerides Ͼ500 mg/dL and may be considered for triglycerides Ͼ200 mg/dL. (Class IIb, Level C)
Lipids should be managed in accordance with U.S. and European guidelines for the general population, with statins as first-line therapy (65) (66) (67) . Statins and fibrates should be used with caution due to increased risk of myopathy, especially in the presence of known myositis or muscular dystrophy (68) . Because cardiovascular risk may be enhanced in lipodystrophic syndromes independent of other risk factors, clinicians may consider applying stricter lipid targets (eg, LDL-cholesterol Ͻ100 mg/dL, non-HDL-cholesterol Ͻ130 mg/dL, triglycerides Ͻ200 mg/ dL), even in patients without diabetes. In addition to diet, fibrates and long-chain omega-3-fatty acids from fish oils have wide clinical use to avoid acute complications of severe hypertriglyceridemia (46) but have not been formally studied. Plasmapheresis has been used in extreme hypertriglyceridemia, but must be repeated frequently (69) . Additional lipid-lowering drugs have not been studied in patients with lipodystrophy.
Hypertension
• Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are first-line treatments for hypertension in patients with diabetes. (Class IIa, Level C)
As in other patients with diabetes, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers should be used for hypertension (70) .
Liver disease
Cholic acid did not reduce hepatic steatosis in patients with FPLD in a double-blind, placebo-controlled crossover study (71) . In NAFLD not associated with lipodystrophy, diet and exercise are first-line treatments (72) , and among pharmacological treatments, vitamin E (in children and adults) (73, 74) and pioglitazone (in adults) (73, 75) have shown the most consistent benefit for liver histopathology. However, these treatments have not been doi: 10.1210/jc.2016-2466 press.endocrine.org/journal/jcemstudied in patients with lipodystrophy and are not approved for NAFLD.
Cosmetic treatment
• Patients should be assessed for distress related to lipodystrophy and referred as necessary to mental health professionals and/or plastic surgeons. (Class IIa, Level C)
Changes in physical appearance from lipodystrophy can cause psychological distress and physical discomfort (eg, from absent fat pads in feet or buttocks). Data regarding cosmetic surgery are limited. For facial lipoatrophy, autologous fat transfer (in APL), dermal fillers (7, 76) , or muscle grafts (77) may be used. Excess fat from the head, neck, or vulva may be surgically reduced or ameliorated by liposuction (7) . Breast implants are helpful in some women (78, 79) . Acanthosis nigricans is improved through successful treatment of insulin resistance (80, 81) . Management of hirsutism is reviewed elsewhere (82) . Oral estrogens are contraindicated in lipodystrophy syndromes due to the risk of severe hypertriglyceridemia and acute pancreatitis. Transdermal estrogens may be safer due to lesser hepatic exposure (83) . There is clinical experience in the safe use of oral progestins and progestincontaining intrauterine devices.
Contraception and hormone replacement therapy
Pregnancy
• Pregnant patients should receive prenatal care from an obstetrician experienced in managing diabetes and a physician experienced in managing lipodystrophy.
(Class IIa, level C) • Should a patient become pregnant while taking metreleptin, clinicians may consider continuing metreleptin if withdrawal would harm the mother and fetus and the patient understands that the effects of metreleptin in pregnancy are unknown (FDA category C), and wishes to continue. (Class IIc, level C)
In patients with lipodystrophy with extreme insulin resistance, worsening insulin resistance during pregnancy may make diabetes management difficult, with attendant fetal risks. Furthermore, metreleptin withdrawal has been associated with rebound hypertriglyceridemia (41), placing patients at risk for pancreatitis, endangering both mother and fetus.
Conclusions
Lipodystrophy syndromes are heterogeneous with diverse pathophysiology. For diagnosis, clinical recognition and physical examination are critical. In management efforts, attention should be paid to metabolic derangements and to many other facets of these syndromes affecting multiple organs and quality of life.
